Jae-Hyeok Kang

Mr. Jae-Hyeok Kang

Hanyang University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
SDSoumyadip Das
Soumyadip Das
ACArun Pandian Chandrasekaran
Arun Pandian Chandrasekaran
BSBharathi Suresh
Bharathi Suresh
SHSaba Haq
Saba Haq
JKJae-Hyeok Kang
Jae-Hyeok Kang
Suresh RamakrishnaSuresh Ramakrishna
Suresh Ramakrishna

Verified
Journal Article
Open access
PDF file
YZYi Zhao
Yi Zhao
JKJae-Hyeok Kang
Jae-Hyeok Kang
KYKi-Chun Yoo
Ki-Chun Yoo
SKSeok-Gu Kang
Seok-Gu Kang
HLHae-June Lee
Hae-June Lee
SLSu-Jae Lee
Su-Jae Lee
Radiation therapy is a current standard-of-care treatment and is used widely for GBM patients. However, radiation therapy still remains a significant barrier to getting a successful outcome due to the therapeutic resistance and tumor recurrence. Understanding the underlying mechanisms of this resistance and recurrence would provide an efficient approach for improving the therapy for GBM treatment. Here, we identified a regulatory mechanism of CD44 which induces infiltration and mesenchymal shift of GBM. Ionizing radiation (IR)-induced K-RAS/ERK signaling activation elevates CD44 expression through downregulation of miR-202 and miR-185 expression. High expression of CD44 promotes SRC activation to induce cancer stemness and EMT features of GBM cells. In this study, we demonstrate that the K-RAS/ERK/CD44 axis is a key mechanism in regulating mesenchymal shift of GBM cells after irradiation. These findings suggest that blocking the K-RAS activation or CD44 expression could provide an efficient way for GBM treatment.

1 June 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YZYi Zhao
Yi Zhao
NKNeha Kaushik
Neha Kaushik
JKJae-Hyeok Kang
Jae-Hyeok Kang
NKNagendra Kumar Kaushik
Nagendra Kumar Kaushik
SSSeung Han Son
Seung Han Son
SLSu-Jae Lee
Su-Jae Lee
Stemness and epithelial–mesenchymal transition (EMT) are two fundamental characteristics of metastasis that are controlled by diverse regulatory factors, including transcription factors. Compared with other subtypes of breast cancer, basal-type or triple-negative breast cancer (TNBC) has high frequencies of tumor relapse. However, the role of alpha-globin transcription factor CP2 (TFCP2) has not been reported as an oncogenic driver in those breast cancers. Here, we show that TFCP2 is a potent factor essential for EMT, stemness, and metastasis in breast cancer. TFCP2 directly bound promoters of EGF and TGFα to regulate their expression and stimulate autocrine signaling via EGFR. These findings indicate that TFCP2 is a new antimetastatic target and reveal a novel regulatory mechanism in which a positive feedback loop comprising EGF/TGFα and AKT can control malignant breast cancer progression. Significance: TFCP2 is a new antimetastatic target that controls TNBC progression via a positive feedback loop between EGF/TGFα and the AKT signaling axis.

4 July 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
YCYan-Hong Cui
Yan-Hong Cui
HKHyeonmi Kim
Hyeonmi Kim
MLMinyoung Lee
Minyoung Lee
JYJoo Mi Yi
Joo Mi Yi
RKRae-Kwon Kim
Rae-Kwon Kim
SLSu-Jae Lee
Su-Jae Lee

15 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JKJae-Hyeok Kang
Jae-Hyeok Kang
MCMi-Young Choi
Mi-Young Choi
YCYan-Hong Cui
Yan-Hong Cui
NKNeha Kaushik
Neha Kaushik
NUNizam Uddin
Nizam Uddin
SLSu-Jae Lee
Su-Jae Lee
Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer

4 June 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YZYi Zhao
Yi Zhao
NSNayeon Shim
Nayeon Shim
YCYan-Hong Cui
Yan-Hong Cui
JKJae-Hyeok Kang
Jae-Hyeok Kang
KYKi-Chun Yoo
Ki-Chun Yoo
SLSu-Jae Lee
Su-Jae Lee